Alvotech, officially known as Alvotech Holdings SA, is a prominent biopharmaceutical company headquartered in Luxembourg (LU). Founded in 2013, Alvotech focuses on the development and manufacturing of high-quality biosimilars, addressing the growing demand for affordable biologic therapies. With a strong operational presence in Europe and North America, the company has established itself as a key player in the biosimilars market. Alvotech's core offerings include a diverse portfolio of biosimilar products that are distinguished by their rigorous development processes and commitment to quality. The company has achieved significant milestones, including successful regulatory approvals and partnerships that enhance its market position. Recognised for its innovative approach, Alvotech continues to lead in the biopharmaceutical industry, striving to improve patient access to essential therapies.
How does Alvotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Alvotech's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Alvotech reported total carbon emissions of approximately 923,000 kg CO2e, with emissions distributed across various scopes: Scope 1 emissions were about 39,800 kg CO2e, Scope 2 emissions totalled approximately 231,000 kg CO2e, and Scope 3 emissions reached about 574,000 kg CO2e. Notably, the Scope 3 emissions were significantly influenced by business travel, which accounted for approximately 386,000 kg CO2e. In 2023, Alvotech's total emissions were approximately 923,000 kg CO2e, with Scope 1 emissions at about 20,000 kg CO2e, Scope 2 emissions at approximately 209,000 kg CO2e, and Scope 3 emissions at around 555,000 kg CO2e. The company has shown a commitment to transparency by disclosing emissions across all three scopes. Despite the detailed emissions reporting, Alvotech has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests a need for further commitment to climate action within the industry context. Overall, Alvotech's emissions data reflects a significant reliance on Scope 3 emissions, particularly from business travel, highlighting an area for potential improvement in their sustainability strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 16,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 202,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 261,000 | 000,000 | 000,000 | 000,000 | 000,000 |
Alvotech's Scope 3 emissions, which increased by 3% last year and increased by approximately 120% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 68% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 67% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alvotech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.